Amanta Healthcare Ltd, a prominent pharmaceutical company specializing in sterile liquid products, launched its Initial Public Offering (IPO) on September 1, 2025, aiming to raise ₹126 crore through a fresh issue of 1 crore equity shares. The IPO, which closed on September 3, 2025, has garnered significant attention from investors, particularly retail and non-institutional investors. This blog provides a detailed look at the IPO, including its objectives, financials, subscription status, and key considerations for investors.
About Amanta Healthcare Ltd
Founded in 1994 and headquartered in Ahmedabad, Gujarat, Amanta Healthcare is a key player in the pharmaceutical sector, focusing on the development, manufacturing, and marketing of sterile liquid products. The company specializes in parenteral solutions, including Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs), produced using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. Its product portfolio spans six therapeutic segments: fluid therapy, formulations, diluents, ophthalmic solutions, respiratory care, and irrigation solutions. Additionally, Amanta manufactures medical devices such as eye lubricants and first-aid solutions.
The company operates a state-of-the-art, ISO and WHO-GMP certified facility in Hariyala, Kheda, Gujarat, spanning 66,852 square meters. This facility houses four LVP lines (two ABFS and two ISBM SteriPort lines) and three SVP lines, supporting a wide range of container types and fill volumes (2ml to 1000ml). Amanta has a robust domestic and international presence, with products registered in 19 countries and exports to 21 countries, including Africa, Latin America, and the UK. It also engages in product partnerships with Indian and global pharmaceutical companies, enhancing its market reach.
IPO Details
Issue Size: ₹126 crore, entirely a fresh issue of 1 crore equity shares with a face value of ₹10 each.
Price Band: ₹120 to ₹126 per share.
Lot Size: 119 shares (minimum investment of ₹14,994 for retail investors at the upper price band).
Subscription Dates: September 1, 2025, to September 3, 2025.
Allotment Date: Expected on September 4, 2025.
Listing Date: Tentatively scheduled for September 9, 2025, on BSE and NSE.
Book Running Lead Manager: Beeline Capital Advisors Pvt. Ltd.
Registrar: MUFG Intime India Pvt. Ltd.
The IPO allocated 50% of shares to Qualified Institutional Buyers (QIBs), 15% to Non-Institutional Investors (NIIs), 35% to Retail Individual Investors (RIIs), and 30% to anchor investors. On August 29, 2025, Amanta raised ₹37.8 crore from six anchor investors, including Bandhan Mutual Fund and Finavenue Capital Trust, at ₹126 per share.
Objectives of the IPO
The proceeds from the IPO will primarily be used for:
Capital Expenditure for SteriPort Line: ₹70 crore for civil construction and equipment purchase to establish a new manufacturing line for SteriPort products at Hariyala, Gujarat.
Capital Expenditure for SVP Line: ₹30.13 crore for setting up a new manufacturing line for Small Volume Parenterals at the same facility.
General Corporate Purposes: The remaining funds will support ongoing business growth and strategic initiatives.
Financial Performance
Amanta Healthcare has shown mixed financial performance in recent years:
Revenue: Decreased by 2% from ₹281.61 crore in FY24 to ₹276.09 crore in FY25.
Profit After Tax (PAT): Increased significantly by 189% from ₹3.63 crore in FY24 to ₹10.5 crore in FY25.
Net Worth: Grew by 45% from ₹66.29 crore in FY24 to ₹96.39 crore in FY25.
Debt-to-Equity Ratio: Stands at 2.02, indicating high leverage compared to its listed peer Denis Chem Lab Ltd. (0.01).
Price-to-Earnings (P/E) Ratio: At the upper price band of ₹126, the IPO is valued at a P/E of 34.59 (post-issue), higher than Denis Chem Lab’s 15.9, suggesting a premium valuation.
In FY25, the Indian IV fluids market, a key segment for Amanta, was valued at approximately ₹45-47 billion, driven by the growth of the healthcare system.
Subscription Status
The IPO saw robust demand, particularly from retail and non-institutional investors:
Day 1 (September 1): Subscribed 4.62 times, with retail at 6.72x, NII at 5.82x, and QIB at 0.04x.
Day 2 (September 2): Subscribed 19.63 times, with NII at 36.41x, retail at 23.35x, and QIB at 0.53x.
Day 3 (September 3, as of 11:15 AM): Subscribed 31.37 times, with NII at 69.14x, retail at 32.66x, and QIB at 0.79x.
The strong retail and NII interest contrasts with the muted response from QIBs, reflecting caution among institutional investors.
Grey Market Premium (GMP)
The Grey Market Premium (GMP) for Amanta Healthcare’s shares fluctuated during the subscription period:
Pre-IPO: GMP ranged from ₹21 to ₹29, with a high of ₹29 on September 1, indicating an estimated listing price of ₹155 (23% premium).
Day 2: GMP dropped to ₹12, suggesting a listing price of ₹138 (9.5% premium).
Day 3: GMP remained at ₹12, reflecting cautious optimism about listing gains.
GMP is an unofficial indicator and subject to market fluctuations, so investors should focus on fundamentals rather than speculative premiums.
Key Strengths
Advanced Manufacturing Capabilities: Amanta’s ISO and WHO-GMP certified facility uses cutting-edge ABFS and ISBM technologies, enabling flexible production from R&D to commercial scale.
Diverse Product Portfolio: 47 products across six therapeutic segments, registered in 120 international jurisdictions, ensure business stability and growth potential.
Strong Market Presence: A robust domestic network with over 320 distributors and exports to 21 countries, supported by partnerships with global pharma companies.
Experienced Leadership: Promoters like Bhavesh Patel and Jayshreeben Patel bring decades of expertise in pharmaceutical manufacturing and regulatory compliance.
Key Risks
Single Facility Risk: Amanta’s operations are concentrated at its Hariyala facility, making it vulnerable to disruptions like fire, flood, or machinery breakdown.
High Debt Levels: A debt-to-equity ratio of 2.02 and high finance costs (45.78% to 62.6% of EBITDA in FY23-FY25) could strain profitability.
Competitive Industry: The company faces pressure from established players like Cipla and Sun Pharma, as well as unlisted competitors, which may impact margins.
Litigation Risks: Pending legal proceedings worth ₹1,465 lakh could adversely affect the business if outcomes are unfavorable.
Past Financial Stress: A 2022 debt restructuring, while resolving immediate pressures, highlights past financial challenges and ongoing high-cost capital obligations.
Analyst Recommendations
Anand Rathi Research: Recommends “Subscribe – Long Term” due to Amanta’s plans to expand manufacturing capacity and deepen customer relationships, despite a high P/E of 46.6x.
Arihant Capital: Assigns a “Neutral” rating, citing growth potential but highlighting execution risks and competitive pressures.
General Advice: Analysts suggest that long-term investors may find value in Amanta’s diversified portfolio and expansion plans, but short-term investors should be cautious due to the high valuation and declining GMP.
Should You Invest?
Amanta Healthcare’s IPO presents a compelling opportunity for investors interested in the growing pharmaceutical sector, particularly in sterile liquid products and IV fluids. The company’s strong product portfolio, international presence, and planned capacity expansion are positive factors. However, the high debt levels, single-facility risk, and premium valuation compared to peers like Denis Chem Lab warrant caution. The significant subscription from retail and NIIs reflects strong market interest, but the muted QIB response and declining GMP suggest tempered expectations for listing gains.
Recommendation: Long-term investors with a high-risk tolerance may consider subscribing, given Amanta’s growth potential in the healthcare sector. Short-term investors should weigh the risks of a potentially modest listing pop and competitive pressures. Always consult a financial advisor and review the Red Herring Prospectus (RHP) before investing.
How to Check Allotment Status
Investors can check the allotment status on the MUFG Intime India website (in.mpms.mufg.com/Initial_Offer/public-issues.html) or BSE/NSE portals by entering their PAN, Application Number, or DP Client ID. The allotment is expected to be finalized on September 4, 2025, with shares credited to demat accounts by September 8, 2025.
Conclusion
Amanta Healthcare Ltd’s IPO is a notable event in the pharmaceutical sector, offering exposure to a company with a strong foothold in sterile liquid products and a growing global presence. While the IPO has seen robust demand, investors should carefully consider the company’s financial health, operational risks, and market dynamics before making a decision. Stay informed and make investment choices aligned with your financial goals.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct thorough due diligence and consult financial advisors before investing.
 for Amanta Healthcare’s shares fluctuated during the subscription period: Pre-IPO: GMP ranged from ₹21 to ₹29, with a high of ₹29 on September 1, indicating an estimated listing price of ₹155 (23% premium).){kind=link}